Hormos Medical Corporation focuses on research and development of products to treat endocrine disorders associated with aging. Hormos Medical develops pharmaceuticals from discovery through clinical phase II and subsequently out-licenses the products to global partners for further development and marketing in co-operation with Hormos. Hormos Medical’s core competence lies in its understanding of the tissue-specific steroid hormone mechanisms at molecular and cellular levels. The company has 10 projects from preclinical to clinical phase II in its portfolio. The company’s product includes Ospemifene (FC-1271a), a selective estrogen receptor modulator (SERM) which is in its late phase II clinical trials for the treatment of postmenopausal osteoporosis.